U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Bleomycin sulfate is an antineoplastic antibiotic isolated from Streptomyces verticillus. It is a mixture of glycopeptide antibiotics containing primarily Bleomycin A2 (~70%) and B2 (~30%). Bleomycin binds to DNA, inhibits DNA synthesis, and causes single strand scission of DNA in vivo and in vitro at specific base sequences.

CNS Activity

CNS Non-penetrant
1,014

Originator

Umezawa, H. et al.
11

Approval Year

1973
98

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Inhibitor
8,297
 20.0 µM [Kd]
DNA
278
Inhibitor
8,297

Conditions

ConditionModalityTargetsHighest PhaseProduct
Squamous cell carcinoma
7
 Primary
Approved
8,429
BLEOMYCIN SULFATE
Hodgkin's lymphoma
34
 Primary
Approved
8,429
BLEOMYCIN SULFATE
Non-Hodgkin's lymphoma
79
 Primary
Approved
8,429
BLEOMYCIN SULFATE
Testicular cancer
7
 Primary
Approved
8,429
BLEOMYCIN SULFATE
Malignant pleural effusion
6
 Primary
Approved
8,429
BLEOMYCIN SULFATE
Head and neck squamous cell carcinoma
32
 Primary
Approved
8,429
BLENOXANE
Malignant pleural effusion
6
 Primary
Approved
8,429
BLENOXANE
Embryonal cell, choriocarcinoma
5
 Primary
Approved
8,429
BLENOXANE
Teratocarcinoma
5
 Primary
Approved
8,429
BLENOXANE
Hodgkin's lymphoma
34
 Primary
Approved
8,429
BLENOXANE
Non-Hodgkin's lymphoma
79
 Primary
Approved
8,429
BLENOXANE
Squamous cell carcinoma, penis
5
 Primary
Approved
8,429
BLENOXANE
Squamous cell carcinoma, cervix
5
 Primary
Approved
8,429
BLENOXANE
Squamous cell carcinoma, vulva
5
 Primary
Approved
8,429
BLENOXANE

PubMed

Patents

20020123477
5
20020168344
5
20040228836
5

Sample Use Guides

In Vivo Use Guide
0.25 to 0.50 units/kg weekly or twice weekly (Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease)
Route of Administration: Intravenous
In Vitro Use Guide
1-200 ug/ml
Substance Class Mixture
Record UNII
7DP3NTV15T
Record Status Validated (UNII)
Record Version
All of the following components must be present:
Structure of BLEOMYCIN A2 SULFATE
Structure of BLEOMYCIN B2 SULFATE
Definition References
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966